Lexeo Therapeutics to Report Third Quarter 2026 Financial Results and Provide LX2020 Business Update on November 16, 2026

Résumé détaillé

Company to host webcast at 8:00 AM ETNEW YORK, Nov. 15, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced it will report third quarter 2026 financial results and provide a business update on the ongoing HEROIC-PKP2 Phase I/II clinical trial of LX2020 for the treatment of PKP2…

NEW YORK, Nov. 15, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (Nasdaq: LXEO), a clinical stage company focused on reshaping the path of genetic diseases with high unmet need, today announced it will report third quarter 2026 financial results and provide a business update on the ongoing HEROIC-PKP2 Phase I/II clinical trial of LX2020 for the treatment of PKP2 arrhythmogenic cardiomyopathy (PKP2-ACM) on Monday, November 16, 2026.

A webcast will be held at 8:00 AM ET on November 16, 2026. Analysts and investors can access the live event through the Events & Presentations page in the Investors section of Lexeo's website. A replay will be available following the call.

About LX2020 LX2020 is an AAV-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy (PKP2-ACM). Mutations in the PKP2 gene are the most common genetic cause of ACM, responsible for approximately 50% of cases and estimated to affect approximately 60,000 people in the United States. PKP2 deficiency in ACM can lead to myocardial cell death, fibrosis, heart dysfunction, rhythm abnormalities, and sudden cardiac death. LX2020 is designed to systemically deliver a functional, full-length PKP2 gene within an adeno-associated viral capsid, AAVrh10, to cardiomyocytes to restore the desmosomal complex and cell-to-cell adhesion.

About Lexeo TherapeuticsLexeo Therapeutics is a New York City-based, clinical stage company dedicated to reshaping the path of genetic disease. By advancing pioneering science, Lexeo seeks to set a new standard in the treatment of cardiovascular and neurological genetic diseases, charting the path to patient outcomes once thought out of reach. The Company is advancing a portfolio of therapeutic candidates designed to address the underlying genetic causes of disease, including LX2006 for Friedreich ataxia (FA), LX2020 for PKP2-ACM, and others in devastating diseases with high unmet need.

Cautionary Note Regarding Forward-Looking StatementsCertain…

Début de l'article, extrait de Yahoo Finance. Pour lire la suite, ouvrez l'article chez le média.